Ariyoshi Jumpei, Momokawa Daiki, Eimori Nao, Kobori Akio, Murakami Akira, Yamayoshi Asako
Department of Biomolecular Engineering, Kyoto Institute of Technology , Matsugasaki, Sakyo-ku, Kyoto 606-8585, Japan.
Department of Chemistry, Graduate School of Science, Kyoto University , Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto 606-8502, Japan.
Bioconjug Chem. 2015 Dec 16;26(12):2454-60. doi: 10.1021/acs.bioconjchem.5b00501. Epub 2015 Nov 8.
MicroRNAs (miRNAs) are known to be important post-transcription regulators of gene expression. Aberrant miRNA expression is associated with pathological disease processes, including carcinogenesis. Therefore, miRNAs are considered significant therapeutic targets for cancer therapy. MiRNAs do not act alone, but exhibit their functions by forming RNA-induced silencing complex (RISC). Thus, the regulation of RISC activity is a promising approach for cancer therapy. MiRNA is a core component of RISC and is an essential to RISC for recognizing target mRNA. Thereby, it is expected that development of the method to promote the release of miRNA from RISC would be an effective approach for inhibition of RISC activity. In this study, we synthesized novel peptide-conjugated oligonucleotides (RINDA-as) to promote the release of miRNA from RISC. RINDA-as showed a high rate of miRNA release from RISC and high level of inhibitory effect on RISC activity.
微小RNA(miRNA)是已知的基因表达重要转录后调节因子。异常的miRNA表达与包括致癌作用在内的病理疾病过程相关。因此,miRNA被认为是癌症治疗的重要治疗靶点。miRNA并非单独起作用,而是通过形成RNA诱导沉默复合体(RISC)来发挥其功能。因此,调节RISC活性是一种有前景的癌症治疗方法。miRNA是RISC的核心组成部分,对于RISC识别靶mRNA至关重要。因此,预计开发促进miRNA从RISC释放的方法将是抑制RISC活性的有效途径。在本研究中,我们合成了新型肽缀合寡核苷酸(RINDA-as)以促进miRNA从RISC释放。RINDA-as显示出从RISC释放miRNA的高比率以及对RISC活性的高水平抑制作用。